Sympathetic vasoconstriction not mediated by aoadrenoceptors has been identified in vitro and in animals but not in humans. We evaluated the effect of ciadrenoceptor blockade on either endogenous vascular sympathetic activation (obtained through the application of a nonhypotensive lower-body negative pressure, -10 mm Hg for 5 minutes) or selective postsynaptic aoadrenoceptor stimulation by exogenous norepinephrine (0.005 ,ug/100 ml forearm tissue/mmn for 3 minutes) in the presence of (3-blockade by propranolol (10 ,ug/100 ml forearm tissue/min for 15 minutes). Drugs were infused into the brachial artery at systemically ineffective rates while continuously monitoring forearm blood flow (by venous plethysmography), intra-arterial mean arterial pressure, and heart rate in patients with essential hypertension. The 
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a-Blockade was obtained by PBZ, whose irreversible alkylating effect avoided displacement from the receptor, at variance with other antagonists of a competitive nature. 10 PBZ was continuously infused for 60 minutes, which is a period sufficient for the full development of its effects.11,12 The drug was administered at a rate of 20 ,ug/100 ml forearm tissue/min, which was chosen to approximate local arterial concentrations of those used in previous experimental studies. 10 The resulting antagonism by PBZ was tested in five patients according to the changes in the vascular effect of three cumulative intra-arterial NE rates (0.005, 0.015, 0.05 ,ug/100 ml forearm tissue/min for 3 minutes each, in presence of propranolol). PBZ abolished forearm vasoconstriction to the first and second NE infusion rate and reduced by 80.5 + 11. 1% the vasoconstriction to the third rate ( Figure 1 ).
Irreversible a-Blockade by Phenoxybenzamine
This series was designed to determine whether or not forearm vasoconstriction is resistant to ablockade.
Six hypertensive patients underwent either LBNP (-10 mm Hg for 5 minutes) or intra-arterial NE (0.005 ,ug/100 ml forearm tissue/min for 3 minutes) in the absence (saline, 0.201 ml/min) or presence of PBZ (20 additional patients by using a doubled infusion rate of PBZ (40 ,tg/100 ml forearm tissue/min).
Neurotransmission Blockade by Bretylium
In this series, we sought evidence for the sympathetic nature of LBNP-mediated vasoconstriction. In addition, we wanted to substantiate the assumption that an amount of drug sufficient to block neurotransmission could be delivered by the intraluminal route to the advential and outer medial vascular layers where sympathetic endings prevail.13 Bretylium tosylate, a neurotransmitter blocker,'4 was used for this purpose. As in the previous series, either LBNP (-10 mm Hg for 5 minutes) or intraarterial NE (0.015 ,ug/100 ml forearm tissue/min for 3 minutes) (both in the presence of propranolol) were administered in the absence and presence of bretylium at 50 ,ig/100 ml forearm tissue/min for 90 minutes (six patients) according to previous human data15 validated in pilot studies.
Experimental Procedure
All studies were performed in a quiet climatized room. A polyethylene cannula (21 gauge, Abbott, Sligo, Ireland) was inserted into the left brachial artery under light local anesthesia (2% lidocaine), and it was connected through stopcocks to a pres- at the infused limb and by 36.7+5.4% (p<0.001) at the control limb ( Figure 2 ). Even at the higher infusion rate of PBZ, exogenous NE had no effect, but LBNP still caused a very consistent residual amount of vasoconstriction in each patient. More important, no significant differences existed between the percent changes in FBF during LBNP after PBZ pretreatment at the two different infusion rates (20 (Figure 3 ).
Discussion
The main finding of our study is the persistence, after a-adrenoceptor blockade, of a residual vascular response to LBNP, a stimulus whose endogenous sympathetic nature was further proved by our bretylium experiments. Considering that PBZ has some preferential a,-antagonistic properties,1"19 a contribution of postsynaptic a2-adrenoceptors20 to this persistent response may be conceived, but we interpret our data to be highly consistent with the presence of sympathetic vasoconstriction not mediated by a-adrenoceptors6 even in humans. In fact, the high degree of antagonism (Figure 1) of the presynaptic feedback control of NE release25 by a-adrenoceptor blockade by PBZ. As a consequence, the amount of neurotransmitter released per unit of stimulus might have increased26 beyond either the levels attained during basal conditions or those achieved during exogenous administration. Because we could not estimate the extent of that change in endogenous NE to adjust the level of our standard exogenous infusion, an overestimation of the effect of PBZ might have resulted. This possibility might be verified by measuring local arterovenous differences in plasma NE. However, no further changes in the vasoconstriction after ablockade could be produced in the present study by doubling PBZ concentrations, which suggests that we were probably close to or at a plateau of antagonism. It was tempting to use even higher infusion rates of PBZ, but ethical reasons prohibited this intervention.
Thus, a-blockade through PBZ in human forearm arterioles blocked the effect of a-adrenoceptor stimulation by exogenous NE (in the presence of propranolol) but could not abolish the vasoconstriction to endogenous sympathetic activation by LBNP. Because similar results were obtained by an even higher concentration of antagonist, sympathetic vasoconstriction not mediated by a-receptors may indeed function even in humans. Our data cannot provide definite answers about the nature of this tentatively identified mechanism, but either adrenoceptors unrelated to the a type, for example, the so called "gamma receptors"5 or cotransmitters such as ATP, neuropeptide Y, and others might be implicated. 6 Ln this regard, the importance of ATP in the constrictor response to electrical stimulation of isolated resistance-sized arterioles was recently documented. 27 Similarly, vasoconstrictor properties of neuropeptide Y have been shown in vitro28 and in animal29 studies, but a relevant role of this substance under physiologic conditions needs confirmation. Questions may also arise about the involvement in the vascular response after a-blockade during LBNP of humoral vasoconstrictor factors such as angiotensin II or antidiuretic hormone. However, either no changes30 or delayed increments31 in plasma renin activity were previously reported in humans, whereas local angiotensin conversion in human forearm vessels has been ruled out.32 On the other hand, the relative insensitivity of antidiuretic hormone to volume stimuli in humans33 and the use of a short-term, nonhypotensive unloading procedure such as ours suggest no role for that hormone, whose vasoconstrictor action at physiologic concentrations was not confirmed by recent data in humans.34 Future studies are needed to further delineate the precise mechanisms of vasoconstriction not mediated by a-adrenoceptors and the physiologic and physiopathologic importance of such vasoconstriction.
